Road to 2025: DXB helping to treat kidney and respiratory disease

Stockheads

01-16

Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead.

Dimerix (ASX:DXB) is working to improve the lives of patients with inflammatory diseases, including both kidney and respiratory diseases. In this episode, Sarah Hughan covers DXB’s ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS), a second licensing deal and regulatory and ethics approval for their clinical trials.

Tune in to find out what to look out for in 2025.

This video was developed in collaboration with Dimerix, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.

Explore More

Investor Guide: Health & Biotech FY2025 featuring Tim Boreham

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2503607979"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503607979\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503607979?lang=zh_CN&edition=fundamental","thumbnail":"https://stockhead.com.au/wp-content/uploads/2024/12/DMX-1200x675-1-640x360.jpg","is_english":true,"pubTime":"2025-01-16 09:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503607979","market":"hk","top_or_hot":-1,"title":"Road to 2025: DXB helping to treat kidney and respiratory disease","media":"Stockheads","content":"<html><body><div><div></div></div><p>Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead.</p><p><strong>Dimerix (ASX:DXB)</strong> is <span>working to improve the lives of patients with inflammatory diseases, including both kidney and respiratory diseases. In this episode, Sarah Hughan covers DXB’s ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS), a second licensing deal and regulatory and ethics approval for their clinical trials. </span></p><p>Tune in to find out what to look out for in 2025.</p><p><i>This video was developed in collaboration with Dimerix, a Stockhead advertiser at the time of publishing.</i></p><p><i>The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.</i></p><div></div><div> <h2>Explore More</h2> <ul><li> <img decoding=\"async\" height=\"169\" sizes=\"(max-width: 300px) 100vw, 300px\" src=\"https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1-300x169.jpg\" srcset=\"https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1-300x169.jpg 300w, https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1-1024x576.jpg 1024w, https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1-768x432.jpg 768w, https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1-640x360.jpg 640w, https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1.jpg 1200w\" width=\"300\"/> <span>Investor Guide: Health &amp; Biotech FY2025 featuring Tim Boreham</span> </li> </ul></div><div></div></body></html>","source":"stockheads_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Road to 2025: DXB helping to treat kidney and respiratory disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoad to 2025: DXB helping to treat kidney and respiratory disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-16 09:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://stockhead.com.au/stockhead-tv/road-to-2025-dxb-helping-to-treat-kidney-and-respiratory-disease/><strong>Stockheads</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead.Dimerix (ASX:DXB) is working to improve the lives of ...</p>\n\n<a href=\"https://stockhead.com.au/stockhead-tv/road-to-2025-dxb-helping-to-treat-kidney-and-respiratory-disease/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DXB","symbol_name":"Deutsche Bank Contingent Capital","start_time":0,"source_url":"https://stockhead.com.au/stockhead-tv/road-to-2025-dxb-helping-to-treat-kidney-and-respiratory-disease/","article_id":"2503607979","we_media_id":null,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2024/12/DMX-1200x675-1-640x360.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503607979","pubTimestamp":1736989984,"columns":[],"sourceInfo":{"source_id":"stockheads_stock","name":"Stockheads"},"weMediaInfo":null,"summary":"Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead.Dimerix  is working to improve the lives of patients with inflammatory diseases, including both kidney and respiratory diseases. In this episode, Sarah Hughan covers DXB’s ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis , a second licensing deal and regulatory and ethics approval for their clinical trials.Tune in to find out what to look out for in 2025.This video was developed in collaboration with Dimerix, a Stockhead advertiser at the time of publishing.The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions. Explore More   Investor Guide: Health & Biotech FY2025 featuring Tim Boreham","collect":0,"end_time":0,"defaultTopTitle":"stockhead.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"DXB":"Deutsche Bank Contingent Capital","FSGS":"First Trust SMID Growth Strength ETF"},"translate_title":"2025年之路：DXB帮助治疗肾脏和呼吸系统疾病","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DXB":1,"FSGS":1},"content_text":"Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead.Dimerix (ASX:DXB) is working to improve the lives of patients with inflammatory diseases, including both kidney and respiratory diseases. In this episode, Sarah Hughan covers DXB’s ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS), a second licensing deal and regulatory and ethics approval for their clinical trials. Tune in to find out what to look out for in 2025.This video was developed in collaboration with Dimerix, a Stockhead advertiser at the time of publishing.The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions. Explore More   Investor Guide: Health & Biotech FY2025 featuring Tim Boreham","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}